Cobo-Calvo, Alvaro
,
Sepúlveda, María
d’Indy, Hyacintha
Armangué, Thais
Ruiz, Anne
Maillart, Elisabeth
Papeix, Caroline
Audoin, Bertrand
Zephir, Helene
Biotti, Damien
Ciron, Jonathan
Durand-Dubief, Francoise
Collongues, Nicolas
Ayrignac, Xavier
Labauge, Pierre
Thouvenot, Eric
Montcuquet, Alexis
Deschamps, Romain
Solà-Valls, Nuria
Llufriu, Sara
Blanco, Yolanda
de Seze, Jerome
Vukusic, Sandra
Saiz, Albert
Marignier, Romain
,
Article History
Received: 28 August 2018
Revised: 11 December 2018
Accepted: 13 December 2018
First Online: 3 January 2019
Change Date: 7 February 2019
Change Type: Correction
Change Details: The original version of this article unfortunately contained a mistake.
Compliance with ethical standards
:
: Cobo-Calvo, Sepulveda, d’Indy, Armangué and Ruiz report no disclosures. Maillart has received consulting and lecturing fees, and travel grants from Biogen Idec, Genzyme, Novartis, Merck Serono, Roche, Sanofi Aventis and Teva Pharma, and research support from Novartis and Roche. Audoin reports no disclosures. Zephir reports no disclosures. Jonathan Ciron serves on scientific advisory board for Merck Serono and Roche, and has received funding for travel and honoraria from Biogen, Novartis, Genzyme, Teva Pharmaceuticals, Merck Serono and Roche, with no relation with the submitted work. Ayrignac and Thouvenot report no disclosures. Montcuquet has received funding for travel from Merck Serono, Teva, Novartis, Sanofi-Genzyme and Biogen. Solà Valls received consulting and travel grants from Biogen Idec, Genzyme-Sanofi, Merck Serono, and Bayer-Schering. Llufriu reports no disclosures. Papeix reports no disclosures. Biotti has received consulting and lecturing fees, and travel grants from Biogen Idec, Genzyme, Novartis, Merck Serono, Roche, Sanofi Aventis and Teva Pharma. Durand-Dubief serves on scientific advisory board for Merck Serono and has received funding for travel and honoraria from Biogen Idec, Merck Serono, Novartis, Sanofi-Genzyme, Roche and Teva. Collongues has received honoraria for consulting or presentation from Biogen Idec, Almirall, Novartis, Merck Serono, LFB, Teva Pharma, Sanofi-Genzyme, Roche, and is a member of the editorial board of the Journal de la Ligue Française contre la Sclérose en plaques, with no relation with the submitted work. Labauge reports no disclosure. Deschamps has received travels grants from Biogen Idec. De Seze reports no disclosures. Vukusic has received consulting and lecturing fees, travel grants and research support from Biogen, Geneuro, Genzyme, Novartis, Merck Serono, Roche, Sanofi Aventis and Teva Pharm. Blanco reports no disclosures. Saiz has received travel funding and/or speaker honoraria from Bayer-Schering, Merck-Serono, Biogen Idec, Sanofi-Aventis, Teva Pharmaceutical Industries, Novartis and Roche. Marignier has received consulting and lecturing fees, travel grants and research support from Bayer-Schering, Biogen Idec, Genzyme, Novartis, Merck Serono, Roche, Sanofi Aventis and Teva Pharma.